Pfiz­er reshuf­fles, split­ting in­to three busi­ness units

Just one day af­ter Pres­i­dent Don­ald Trump ha­rangued Pfiz­er CEO Ian Read in­to de­lay­ing its drug pric­ing hikes, the phar­ma gi­ant has an­nounced it’s split­ting up in­to three busi­ness units: in­no­v­a­tive med­i­cines, es­tab­lished med­i­cines, and con­sumer health­care.

Un­der the in­no­v­a­tive meds group fall Pfiz­er’s biosim­i­lars and the hos­pi­tal busi­ness unit, which in­cludes an­ti-in­fec­tives and ster­ile in­jecta­bles. Es­tab­lished med­i­cines will in­clude the ma­jor­i­ty of Pfiz­er’s off-patent brands, like Vi­a­gra and Lyri­ca. Then there’s the con­sumer health­care unit, which will in­clude the com­pa­ny’s over-the-counter med­i­cines. But that one may soon be on the chop­ping block.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER